Literature DB >> 10075272

Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary.

J W Chow1, V L Yu.   

Abstract

Whether combination antimicrobial therapy is more efficacious than monotherapy for gram-negative bacteraemia remains controversial. Although there are theoretical advantages to combination therapy that are buttressed by in vitro and animal studies, the data from studies of patients with gram-negative bacteraemias have been conflicting. A review of selected clinical studies suggests that combination therapy is associated with improved outcome typically only in severely ill patients and its efficacy may be further limited to those with Pseudomonas aeruginosa, Klebsiella spp. or Enterobacter spp. bacteraemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10075272     DOI: 10.1016/s0924-8579(98)00060-0

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  100 in total

1.  Effectiveness of combination antimicrobial therapy for Pseudomonas aeruginosa bacteremia.

Authors:  Eric Chamot; Emmanuelle Boffi El Amari; Peter Rohner; Christian Van Delden
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

2.  In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.

Authors:  Jimmy Yoon; Carl Urban; Christian Terzian; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli.

Authors:  Carl Urban; Noriel Mariano; James J Rahal
Journal:  Antimicrob Agents Chemother       Date:  2010-04-05       Impact factor: 5.191

4.  Predicting mortality in burn patients with bacteraemia.

Authors:  Alexandra Ceniceros; Sonia Pértega; Rita Galeiras; Mónica Mourelo; Eugenia López; Javier Broullón; Dolores Sousa; David Freire
Journal:  Infection       Date:  2015-10-08       Impact factor: 3.553

Review 5.  Multidrug evolutionary strategies to reverse antibiotic resistance.

Authors:  Michael Baym; Laura K Stone; Roy Kishony
Journal:  Science       Date:  2016-01-01       Impact factor: 47.728

Review 6.  Optimal therapy for severe pneumococcal community-acquired pneumonia.

Authors:  Manel Luján; Miguel Gallego; Jordi Rello
Journal:  Intensive Care Med       Date:  2006-05-10       Impact factor: 17.440

7.  Evidence-based Medicine in Infectious Diseases and Microbiology: Still a Long Way to Go.

Authors:  Jan Verhoef
Journal:  Curr Infect Dis Rep       Date:  2003-04       Impact factor: 3.725

8.  Clinical Features and Risk Factors for Development of Breakthrough Gram-Negative Bacteremia during Carbapenem Therapy.

Authors:  Ji-Yong Lee; Cheol-In Kang; Jae-Hoon Ko; Woo Joo Lee; Hye-Ri Seok; Ga Eun Park; Sun Young Cho; Young Eun Ha; Doo Ryeon Chung; Nam Yong Lee; Kyong Ran Peck; Jae-Hoon Song
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae.

Authors:  David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Keith S Kaye; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2014-12-09       Impact factor: 5.790

10.  Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance.

Authors:  D van Duin; E D Cober; S S Richter; F Perez; M Cline; K S Kaye; R C Kalayjian; R A Salata; S R Evans; V G Fowler; R A Bonomo
Journal:  Clin Microbiol Infect       Date:  2014-12-12       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.